RT Journal Article SR Electronic T1 Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence JF The Journal of the American Board of Family Medicine JO J Am Board Fam Med FD American Board of Family Medicine SP S141 OP S146 DO 10.3122/jabfm.2021.S1.200236 VO 34 IS Supplement A1 Robbins, Jonathan L. A1 Englander, Honora A1 Gregg, Jessica YR 2021 UL http://www.jabfm.org/content/34/Supplement/S141.abstract AB Prescription opioid dependence remains a major source of morbidity and mortality in the United States. Patients previously on high-dose opioids may poorly tolerate opioid tapers. Current guidelines support the use of buprenorphine therapy in opioid-tapering protocols, even among patients without a diagnosis of opioid use disorder. Buprenorphine microinduction protocols can be used to transition patients to buprenorphine therapy without opioid withdrawal. From November 2019 to April 2020, we transitioned 8 patients on high-dose prescribed opioids for pain to sublingual buprenorphine-naloxone using a microdose protocol without any evidence of precipitated withdrawal. Six of these patients remain on buprenorphine-naloxone and report improved analgesia. Because of its simplicity, the buprenorphine microinduction protocol can be easily adapted for telemedicine and may help to prevent unnecessary clinic visits and opioid-related admissions in the setting of social distancing regulations during the coronavirus 2019 pandemic.